Compare Ascendis Pharma A/S (ASND) vs Wix.Com Ltd (WIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Wix.Com Ltd — how do they compare? Ascendis Pharma A/S trades at $258 (market cap $16.67B), while Wix.Com Ltd trades at $66.06 (market cap $2.79B). The key difference: Ascendis Pharma A/S is far larger — about 6× Wix.Com Ltd's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Wix.Com Ltd nearer its low. Which is the better fit depends on your goals.
| ASND | WIX | |
|---|---|---|
Market Cap | $16.67B | $2.79B |
Sector | Health | Technology |
52-Week High | $277.18 | $184.24 |
52-Week Low | $189.74 | $40.43 |
Enterprise Value | $17.04B | $3.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $255.50, showing minimal daily movement with a slight decline of 0.05%. The stock maintains a bullish technical outlook with strong moving average signals, while oscillators remain neutral. Fundamentally, the company demonstrates impressive revenue growth from $51M in 2022 to $720M in 2025, though it remains unprofitable with a net loss of $228M. Analyst sentiment is overwhelmingly positive with 92% buy ratings and a $309.75 consensus price target representing 21% upside potential.
ASND presents a compelling growth story with multiple product launches driving revenue expansion, but carries significant execution risk as the company transitions to profitability. The negative shareholder equity and high debt levels require careful monitoring, though positive cash flow generation in 2025 marks an important inflection point. The stock's premium valuation reflects expectations for continued growth in its rare endocrine franchise.
Wix trades at $62.43, up 3.7% today, with a bullish technical signal and strong analyst consensus. Recent earnings show mixed results, beating estimates in three of the last four quarters, while revenue grew to $1.99B in 2025. The stock faces headwinds from a class action lawsuit following a Q1 2026 miss and a 27% price drop in May 2026.
The outlook is cautiously optimistic given Wall Street's $79.75 price target and 66% buy ratings, but litigation over financial disclosures and negative shareholder equity pose significant risks. Revenue growth remains a key catalyst, though profitability volatility requires monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Wix.Com Ltd
Wix.com Ltd is a cloud-based development platform provider for millions of registered users worldwide. The company is engaged in web development and management that provides an easy-to-use powerful cloud-based platform of products through a freemium model. Its core products consist of three web editors: the Wix Editor, intended for users with basic technological skills, Wix ADI, intended for novice users and Corvid, intended for more tech-savvy users. The company's web development technology is built based on HTML5 and offers HTML5 compatible capabilities, web design and layout tools, domain hosting, and other marketing and workflow management applications and services. The geographic segments include North America, Europe, Latin America, Asia and others.
Read more on WIX →
